Dapagliflozin in Acute Cardiovascular Conditions
Bibliographic record
Abstract
BACKGROUND: Sodium-glucose cotransporter-2 inhibitors improve clinical outcomes across various settings, but their use in critically ill patients hospitalized for acute cardiovascular conditions remains unexplored. OBJECTIVES: Secondary analysis aimed to: 1) determine whether treatment effects of dapagliflozin differ between critically ill patients admitted for cardiovascular vs noncardiovascular reasons; and 2) to investigate acute effects of in-hospital dapagliflozin initiation in patients with acute cardiovascular conditions. METHODS: This secondary analysis of the DEFENDER (Dapagliflozin in Critically Ill Patients with Acute Organ Dysfunction) trial, which randomized 507 critically ill patients to dapagliflozin 10 mg daily or standard care alone, compared cardiovascular (n = 162) vs noncardiovascular (n = 345) admissions. The primary outcome was a hierarchical composite of hospital mortality, initiation of kidney replacement therapy, and intensive care unit length of stay through 28 days, analyzed by win ratio; median in-hospital follow-up was 9 days (Q1-Q3: 5-17 days). Daily parameters were analyzed in 134 cardiovascular patients using Bayesian mixed models. RESULTS: The win ratio for the primary outcome was 0.94 (95% CI: 0.77-1.15) in the cardiovascular subgroup and 1.05 (95% CI: 0.91-1.21) in the noncardiovascular subgroup (interaction P = 0.69). Serious adverse events were similar between arms in both subgroups. In cardiovascular patients, dapagliflozin increased urine output by 212 mL/day (95% credible interval: 30-392) and decreased fluid balance by -237 mL/day (95% credible interval: -447 to -26) with minimal increases in norepinephrine (0.01 μg/kg/min) and dobutamine (0.43 μg/kg/min) requirements. CONCLUSIONS: No treatment effect heterogeneity was observed based on intensive care unit admission reason. Dapagliflozin use in critically ill cardiovascular patients appeared safe, demonstrating a modest diuretic effect with minimal vasoactive support increases, warranting further investigation. (Dapagliflozin in Patients With Critical Illness [DEFENDER]; NCT05558098).
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".